Nomura Asset Management Co. Ltd. reduced its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 17.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 372,764 shares of the company’s stock after selling 80,600 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $6,561,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in TEVA. San Francisco Sentry Investment Group CA bought a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $106,000. Bronfman E.L. Rothschild L.P. raised its position in Teva Pharmaceutical Industries by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the last quarter. Penserra Capital Management LLC bought a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $129,000. Shelter Mutual Insurance Co bought a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $133,000. Finally, Fayez Sarofim & Co. bought a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $204,000. 52.05% of the stock is owned by institutional investors and hedge funds.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up $0.68 on Friday, hitting $15.00. The stock had a trading volume of 15,848,000 shares, compared to its average volume of 15,675,085. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The firm has a market cap of $14,559.28, a P/E ratio of 3.31 and a beta of 0.55. Teva Pharmaceutical Industries Limited has a 12 month low of $10.85 and a 12 month high of $38.31.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.085 dividend. The ex-dividend date is Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.27%. Teva Pharmaceutical Industries’s dividend payout ratio is presently -12.10%.

TEVA has been the subject of several analyst reports. BTIG Research raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Monday, September 11th. Gabelli reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 13th. ValuEngine upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Evercore ISI set a $38.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, TheStreet downgraded Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a report on Friday, August 25th. Seven investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $21.65.

TRADEMARK VIOLATION WARNING: “Nomura Asset Management Co. Ltd. Has $6.56 Million Position in Teva Pharmaceutical Industries Limited (TEVA)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/nomura-asset-management-co-ltd-has-6-56-million-position-in-teva-pharmaceutical-industries-limited-teva/1751967.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.